A Phase 1, Randomized , Double Blind, Single Ascending Dose Study to Investigate Safety, Tolerability and PK of NP10679 in Healthy Adults
Phase of Trial: Phase I
Latest Information Update: 17 Jan 2020
Price : $35 *
At a glance
- Drugs NP 10679 (Primary)
- Indications Epilepsy; Pain; Subarachnoid haemorrhage
- Focus Adverse reactions
- Sponsors NeurOp
- 11 Mar 2019 Status changed from recruiting to completed.
- 20 Aug 2018 Planned End Date changed from 21 Aug 2018 to 10 Oct 2018.
- 20 Aug 2018 Planned primary completion date changed from 2 Aug 2018 to 2 Sep 2018.